Haploidentical Hematopoietic Stem Cell Transplantation



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any - 22
Updated:4/17/2018
Start Date:January 2015
End Date:April 2023
Contact:Allistair Abraham, MD
Email:AAbraham@childrensnational.org
Phone:2024765772

Use our guide to learn which trials are right for you!

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE AND THALASSEMIA USING CD34+ POSITIVE SELECTED GRAFTS

The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in
patients with sickle cell disease and thalassemia. The purpose of the study is to assess the
safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell
transplantation.

Research subjects will undergo reduced intensity conditioning (Hydroxyurea, ATG, Fludarabine,
Thiotepa, Melphalan) followed by infusion of a peripheral blood stem cell graft collected
from haploidentical family donors that are CD34+ positively selected using the CliniMACS
device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant
and then tapered off by one year

The use of the CliniMACS device for CD34 selection will be performed at CNMC through
cross-reference of the master file for CliniMACS CD34+ Reagent by Milteyni Biotech (BB-MF
8061).

CliniMACs is an electromechanical device intended to isolate certain cell subsets from mixed
cell populations. When used in combination with the CliniMACs CD34 reagent, it is possible to
prepare extremely pure populations of CD34+ cells with upwards of 5 logs depletion of
contaminating T cells within a closed and sterile system.

We intend to use this system to select cells from HLA haploidentical related donors who have
been mobilized with G-CSF prior to stem cell collection. Since previous investigations of
this strategy in adult patients have not translated into enhanced long term survival, we
intend to limit this protocol to patients under the age of 22 as they have more rapid immune
reconstitution.

Inclusion Criteria:

- First allogeneic transplant

- Age up to 22 years

- Patients with severe sickle cell disease (stroke, elevated TCD velocities, >2 acute
chest syndrome, ongoing chronic red cell transfusion > 6 months)

- Patients with transfusion dependent thalassemia and evidence of iron overload

- Patients must have a related donor that is HLA-matched at >/=4 of 8 but <8/8 HLA-A,
-B, -C and -DRB1

- Cardiac function: Shortening fraction >25%; ejection fraction >40%

- Estimated creatinine clearance greater than 50 mL/minute

- Pulmonary function: DLCO ≥40% (adjusted for hemoglobin) and FEV1≥50%, oxygen
saturation>91%

- Liver function: direct (conjugated) bilirubin < 2x the upper limit of normal and
ALT/AST < 2.5x the upper normal limit.

- Signed informed consent.

Exclusion Criteria:

- Life expectancy less than 6 months

- Patients with uncontrolled bacterial, viral or fungal infections (undergoing
appropriate treatment and with progression of clinical symptoms) within 1 month prior
to conditioning. Patients with febrile illness or suspected minor infection should
await clinical resolution prior to starting conditioning.

- Pregnant or breastfeeding patients

- Patients seropositive for the human immunodeficiency virus (HIV)

- Patient with active Hepatitis B or C determined by serology and/or NAAT

- Active hepatitis, bridging fibrosis or cirrhosis on liver biopsy (biopsy required for
patients on chronic transfusion therapy for > 1 year and evidence of iron overload
with ferritin >1000 ng/mL)

- Patients with suitable 8/8 HLA matched related and unrelated donors
We found this trial at
1
site
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials